Novo Nordisk faces market challenges and patent expirations

Novo Nordisk, a leading Danish pharmaceutical company, is navigating a period of market volatility following significant breakthroughs in the diabetes and anti-obesity sectors. While the company reached an all-time high in 2024 driven by products such as Ozempic, Rybelsus, and Wegovy, it has recently experienced clinical and commercial setbacks resulting in a loss of market value.

Looking ahead, the company faces the potential for generic competition as U.S. patents for its key active ingredients are set to expire in 2032. To counter these challenges, Novo Nordisk is advancing its pipeline, specifically focusing on CagriSema. This next-generation medicine combines semaglutide and cagrilintide, showing higher efficacy in Phase 3 obesity studies than its individual components.